ACADIA Pharmaceuticals Inc.
ACAD
$20.81
$0.090.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.39% | 11.27% | 9.34% | 18.70% | 12.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.39% | 11.27% | 9.34% | 18.70% | 12.36% |
| Cost of Revenue | -9.43% | 28.10% | 4.47% | 19.40% | 44.78% |
| Gross Profit | 26.22% | 2.56% | 12.46% | 18.23% | -6.38% |
| SG&A Expenses | 19.63% | 0.08% | 14.05% | 17.02% | 16.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.54% | 11.03% | 9.77% | 18.05% | 28.82% |
| Operating Income | 148.87% | 12.99% | 6.36% | 26.82% | -80.00% |
| Income Before Tax | -83.66% | 14.92% | 8.15% | 32.27% | 305.73% |
| Income Tax Expenses | -1,525.64% | -549.99% | 257.11% | 97.71% | 384.59% |
| Earnings from Continuing Operations | 90.32% | 119.07% | -20.14% | 14.69% | 213.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.32% | 119.07% | -20.14% | 14.69% | 213.87% |
| EBIT | 148.87% | 12.99% | 6.36% | 26.82% | -80.00% |
| EBITDA | 66.49% | 13.13% | 6.97% | 7.25% | -66.64% |
| EPS Basic | 87.17% | 115.35% | -21.22% | 13.23% | 210.58% |
| Normalized Basic EPS | 77.51% | 13.00% | 6.62% | 30.61% | -58.31% |
| EPS Diluted | 86.20% | 112.77% | -20.55% | 10.00% | 213.27% |
| Normalized Diluted EPS | 75.82% | 11.85% | 6.58% | 31.35% | -57.94% |
| Average Basic Shares Outstanding | 1.68% | 1.72% | 1.37% | 1.22% | 1.05% |
| Average Diluted Shares Outstanding | 2.80% | 2.69% | 1.51% | 0.63% | 0.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |